Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 27, 2005

Primary Completion Date

April 7, 2006

Study Completion Date

April 7, 2006

Conditions
Infections, StreptococcalStreptococcus Pneumoniae Vaccines
Interventions
BIOLOGICAL

Pneumococcal (vaccine)

Trial Locations (32)

10315

GSK Investigational Site, Berlin

12627

GSK Investigational Site, Berlin

12679

GSK Investigational Site, Berlin

13055

GSK Investigational Site, Berlin

13409

GSK Investigational Site, Berlin

14197

GSK Investigational Site, Berlin

17192

GSK Investigational Site, Waren

18146

GSK Investigational Site, Rostock

32427

GSK Investigational Site, Minden

32549

GSK Investigational Site, Bad Oeynhausen

40699

GSK Investigational Site, Erkrath

41061

GSK Investigational Site, Mönchengladbach

41236

GSK Investigational Site, Mönchengladbach

42579

GSK Investigational Site, Heiligenhaus

46145

GSK Investigational Site, Oberhausen

47574

GSK Investigational Site, Goch

47877

GSK Investigational Site, Willich

48159

GSK Investigational Site, Münster

54294

GSK Investigational Site, Trier

54568

GSK Investigational Site, Gerolstein

55131

GSK Investigational Site, Mainz

65205

GSK Investigational Site, Wiesbaden

67227

GSK Investigational Site, Frankenthal

68167

GSK Investigational Site, Mannheim

71672

GSK Investigational Site, Marbach

82327

GSK Investigational Site, Tutzing

86720

GSK Investigational Site, Nördlingen

98724

GSK Investigational Site, Neuhaus am Rennweg

99425

GSK Investigational Site, Weimar

04178

GSK Investigational Site, Leipzig

09366

GSK Investigational Site, Stollberg

07356

GSK Investigational Site, Bad Lobenstein

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00307541 - Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine | Biotech Hunter | Biotech Hunter